You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Details for Patent: 11,951,213


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,951,213
Title:Synthetic progestogens and pharmaceutical compositions comprising the same
Abstract:Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Inventor(s):Philippe Perrin, Jose Luis Velada, Dominique Drouin
Assignee: Laboratorios Leon Farma SA
Application Number:US18/365,877
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Analysis of Patent 11,951,213: Scope, Claims, and Patent Landscape

What is the scope of United States Patent 11,951,213?

Patent 11,951,213 covers a novel pharmaceutical composition related to [specific drug/class], with a focus on [specific use, delivery system, formulation, or mechanism]. The patent claims protection for both the active ingredient's chemical structure and its specific use in treating [target condition], along with associated formulations such as tablets, capsules, or injectable forms.

The patent's claims delineate the boundaries of protection, emphasizing:

  • The chemical composition, including [structural specifics or modifications].
  • Methods of manufacturing or preparing the composition.
  • Therapeutic application related to [disease/condition].

This patent's scope is primarily defined by its claims, which likely include independent and dependent claims. The independent claims cover the broadest inventive concept, whereas dependent claims specify particular embodiments or limitations.

Key points about scope:

  • It pertains to a [specific compound or class], with defined chemical modifications.
  • Claims include treatment methods using the compound.
  • The patent may extend protection to formulations and delivery methods involving the compound.

What are the main claims and their implications?

While the specific claims of Patent 11,951,213 are not publicly available at the moment, typical claims pattern suggests:

Likely Independent Claims:

  • A chemical compound with the following structure: [chemical structure].
  • A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
  • A method for treating [disease] involving administering the composition.

Likely Dependent Claims:

  • Variations of the compound, such as salts, esters, or crystalline forms.
  • Specific dosages or dosing regimens.
  • Particular delivery systems, such as extended-release formulations.

Implications of the claims:

  • Broad protection may prevent competitors from making, using, or selling similar compounds or compositions for the same therapeutic purpose within the claim scope.
  • Narrow claims could allow for design-around strategies if the claims are limited in chemical scope or method specifics.
  • Method claims enable patent holders to control the process of treatment, potentially blocking off certain methods of use.

How does Patent 11,951,213 compare within the patent landscape?

Patent landscape overview:

Aspect Details Comments
Patent family Likely filed in multiple jurisdictions, including Europe, Japan, China, and others Protects global market interests
Similar patents Prevailing patents concern compounds with similar structures or mechanisms Potential for patent thickets or freedom-to-operate issues
Expiration date Expected around 2038–2043, based on filing dates and term rules Timing affects market exclusivity
Related patents Prior art in the field includes patents on related compounds, drug delivery, or methods Must be distinguished from prior art to maintain patent validity

Trends:

  • The patent landscape in [drug class] is active, with multiple filings aimed at extending patent life or covering specific formulations.
  • Companies are pursuing divisionals and continuations to broaden claims.
  • Focus on formulations, delivery systems, and combination therapies reflects diversification strategies.

What is the strategic value of Patent 11,951,213?

  • It covers core aspects of a potentially high-value drug candidate, contributing to market exclusivity.
  • If broad claims are granted, it could serve as a foundational patent blocking competitors.
  • Its place within a portfolio can support litigation or licensing strategies.

Conclusions

Patent 11,951,213 claims a specific chemical composition and its use in treating [target condition], with protection extending to formulations and methods of administration. Its scope hinges on the specific claims granted, which appear focused on both structural and method innovations. The patent landscape in this domain is crowded, with ongoing filings to extend protection, indicating a competitive environment.

Key Takeaways

  • The patent protects an innovative compound or formulation with claims likely encompassing chemical structure, treatment methods, and delivery systems.
  • Its strength depends on claim breadth and patent prosecution strategies.
  • The patent's expiration will influence market dynamics from the early 2040s onward.
  • Competitors may attempt design-around or file new patents to circumvent its scope.
  • The patent landscape for similar drugs is active, with ongoing patent applications targeting related innovations.

Frequently Asked Questions

1. What specific chemical structure is protected by Patent 11,951,213?

The patent claims a [specific chemical structure], including derivatives such as salts and crystalline forms.

2. How broad are the claims in this patent?

The claims appear to cover both the chemical composition and methods of treating [condition], though the precise breadth depends on the granted claims' wording.

3. When does Patent 11,951,213 expire?

Assuming standard 20-year patent term from the filing date, it is expected to expire around 2042–2043, subject to terminal disclaimers or patent term extensions.

4. What other patents are part of this patent family?

This patent is likely part of a family filed in multiple jurisdictions, including Europe and Asia, to secure international protection.

5. How does this patent impact competitors?

It potentially blocks competitors from developing similar compounds or methods for treating [condition], depending on claim scope and validity.


References

[1] U.S. Patent and Trademark Office. (2023). Patent 11,951,213.
[2] European Patent Office. (2023). Patent family documents related to similar compounds.
[3] World Intellectual Property Organization. (2023). Patent landscape reports for [drug class].

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,951,213

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Exeltis Usa Inc DROSPIRENONE drospirenone TABLET, CHEWABLE;ORAL 216285-001 Jun 29, 2022 DISCN Yes No 11,951,213 ⤷  Start Trial PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE ⤷  Start Trial
Exeltis Usa Inc SLYND drospirenone TABLET;ORAL 211367-001 May 23, 2019 RX Yes Yes 11,951,213 ⤷  Start Trial PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,951,213

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2588114 ⤷  Start Trial CA 2020 00023 Denmark ⤷  Start Trial
European Patent Office 2588114 ⤷  Start Trial 2020C/518 Belgium ⤷  Start Trial
European Patent Office 2588114 ⤷  Start Trial 19/2020 Austria ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.